COGT (STOCKS)
Cogent Biosciences, Inc. Common Stock
$37.750000
-1.230000 (-3.16%)
Prev close: $38.980000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Andrew R. Robbins
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6,501.17M
- Employees
- 205
- P/E (TTM)
- -15.26
- P/B (TTM)
- 14.31
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
8
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.60 | $-0.55 | -0.0484 | -8.77% |
|
Dec 2025 (Q4)
|
$-0.64 | $-0.53 | -0.1098 | -20.91% |
|
Sep 2025 (Q3)
|
$-0.50 | $-0.54 | +0.0382 | +7.10% |
|
Jun 2025 (Q2)
|
$-0.53 | $-0.60 | +0.0685 | +11.45% |
Financial Statements
| Revenues | $0.00 |
| Costs And Expenses | $389.09M |
| Nonoperating Income/Loss | $11.91M |
| Depreciation and Amortization | $2.67M |
| Research and Development | $290.72M |
| Operating Income/Loss | -$389.09M |
| Income/Loss From Continuing Operations After Tax | -$377.18M |
| Income/Loss From Continuing Operations Before Tax | -$379.60M |
| Net Income/Loss | -$377.18M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$377.18M |
| Net Income/Loss Available To Common Stockholders, Basic | -$377.18M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.16 |
| Diluted Earnings Per Share | -$2.16 |
| Basic Average Shares | 311,210,504 |
| Diluted Average Shares | 311,210,504 |
| Assets | $834.55M |
| Current Assets | $804.82M |
| Noncurrent Assets | $29.73M |
| Fixed Assets | $4.78M |
| Other Non-current Assets | $24.95M |
| Liabilities | $302.16M |
| Current Liabilities | $59.30M |
| Accounts Payable | $7.49M |
| Wages | $12.50M |
| Other Current Liabilities | $39.31M |
| Noncurrent Liabilities | $242.86M |
| Long-term Debt | $223.46M |
| Other Non-current Liabilities | $19.41M |
| Equity | $532.39M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $532.39M |
| Liabilities And Equity | $834.55M |
| Net Cash Flow From Operating Activities | -$307.55M |
| Net Cash Flow From Operating Activities, Continuing | -$307.55M |
| Net Cash Flow From Investing Activities | -$499.99M |
| Net Cash Flow From Investing Activities, Continuing | -$499.99M |
| Net Cash Flow From Financing Activities | $861.53M |
| Net Cash Flow From Financing Activities, Continuing | $861.53M |
| Net Cash Flow | $53.99M |
| Net Cash Flow, Continuing | $53.99M |
| Comprehensive Income/Loss | -$377.96M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$377.96M |
| Other Comprehensive Income/Loss | -$783.00K |